(2024, September) Retatrutide is a novel triple-agonist targeting GLP-1, GIP, and glucagon receptors, showing in phase 2 trials that it can deliver remarkably large weight losses (up to ~24% over 48 weeks in people with obesity) along with strong improvements in HbA1c, lipid profiles, liver fat (in NAFLD), insulin sensitivity, and other cardiometabolic markers
Pair with a protein rich breakfast
Take 1 capsule daily on an empty stomach (30 minutes before a meal), or as directed by your healthcare provider
In order for oxidative phosphorylation to proceed, two principal conditions must be met
Ensure your diabetes is well-controlled on your usual treatment
Diet, Exercise, and Lifestyle: Optimizing Your GLP-1 Medication Journey Achieving the best weight loss with GLP-1 medication often involves a vital approach that considers various individual factors influencing your unique treatment experience